OGN · Organon & Co.
$13.72
+0.00 (+0.00%)
At close · Aug 14
Going-concern doubt
— cleared Jul 31, 2026
The latest filing no longer states the doubt (first flagged May 4, 2026).
View the 10-Q filed Jul 31, 2026Market Cap
$3.60B
Shares
262.61M
Organon & Co. Earnings Call Transcripts
Every quarterly earnings call for Organon & Co. (OGN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼0.6%
$1.58B
$234.00M
'22 Q2
22-08-04
▼3.9%
$1.54B
$227.00M
'22 Q3
22-11-03
▼7.4%
$1.49B
$108.00M
'22 Q4
23-02-16
▼1.9%
$1.54B
$177.00M
'23 Q1
23-05-04
▲1.5%
$1.61B
$242.00M
'23 Q2
23-08-08
▼1.2%
$1.52B
$58.00M
'23 Q3
23-11-02
▲7.6%
$1.60B
$546.00M
'23 Q4
24-02-15
▲5.5%
$1.62B
$201.00M
'24 Q1
24-05-02
▼0.1%
$1.61B
$195.00M
'24 Q2
24-08-06
▲4.1%
$1.58B
$359.00M
'24 Q3
24-10-31
▼0.4%
$1.59B
$109.00M
'24 Q4
25-02-13
▼6.7%
$1.51B
$87.00M
'25 Q1
25-05-01
▼0.8%
$1.59B
$145.00M
'25 Q2
25-08-05
▲1.3%
$1.60B
$160.00M
'25 Q3
25-11-10
▼5.3%
$1.51B
−$205.00M
'25 Q4
26-02-12
LATEST
▼3.5%
$1.46B
$146.00M
'26 Q1
26-04-30
Annual General Meeting
Investor event
2026-07-23
Organon & Co. 2026 Special Meeting of Stockholders
No reported result — non-financial event
Audio
Transcript
Slides
Annual General Meeting
Investor event
2026-06-09
Organon & Co. 2026 Annual Meeting of Shareholders
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Organon & Co. Q1 FY2026 Earnings Call
Revenue
$1.46B
▼ 3.5% YoY Diluted EPS
$0.55
▲ 66.7% YoY Gross margin
53.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Organon & Co. Q4 FY2025 Earnings Call
Balanced tone
Nexplanon headwinds
Established brands / respiratory reset
Vtama growth
Revenue
$1.51B*
▼ 5.3% YoY Gross margin
49.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Organon & Co. Q3 FY2025 Earnings Call
Balanced tone
Nexplanon outlook
Business development and pipeline
Leadership transition and CEO search
Revenue
$1.60B
▲ 1.3% YoY Diluted EPS
$0.61
▼ 55.8% YoY Gross margin
53.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Organon & Co. Q2 FY2025 Earnings Call
Positive tone
Vtama growth and access
Nexplanon 5-year indication and U.S. funding risk
Women's Health franchise
Revenue
$1.59B
▼ 0.8% YoY Diluted EPS
$0.56
▼ 25.3% YoY Gross margin
54.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Organon & Co. Q1 FY2025 Earnings Call
Positive tone
Vtama launch in atopic dermatitis
Guidance affirmation and free cash flow
Tariff exposure and supply chain
Revenue
$1.51B
▼ 6.7% YoY Diluted EPS
$0.33
▼ 57.7% YoY Gross margin
55.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Organon & Co. Q4 FY2024 Earnings Call
Confident tone
Vtama and Dermavant Launch
Nexplanon Growth and 5-Year Indication
Atozet Loss of Exclusivity Headwind
Revenue
$1.59B*
▼ 0.4% YoY Gross margin
56.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Organon & Co. Q3 FY2024 Earnings Call
Confident tone
Revenue Growth and Guidance
VTAMA / Dermavant Acquisition
Adjusted EBITDA Margin
Revenue
$1.58B
▲ 4.1% YoY Diluted EPS
$1.38
▲ 500% YoY Gross margin
58.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Organon & Co. Q2 FY2024 Earnings Call
Confident tone
Fertility business challenges
Biosimilars franchise momentum
China market dynamics
Revenue
$1.61B
▼ 0.1% YoY Diluted EPS
$0.75
▼ 21.1% YoY Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Organon & Co. Q1 FY2024 Earnings Call
Confident tone
Women's Health Franchise (NEXPLANON)
Biosimilars Franchise
Established Brands and Migraine Assets
Revenue
$1.62B
▲ 5.5% YoY Diluted EPS
$0.78
▲ 13% YoY Gross margin
59.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Organon & Co. Q4 FY2023 Earnings Call
Confident tone
Revenue growth and 2024 guidance
Women's Health franchise
Free cash flow and leverage
Revenue
$1.60B*
▲ 7.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Organon & Co. Q3 FY2023 Earnings Call
Revenue
$1.52B
▼ 1.2% YoY Diluted EPS
$0.23
▼ 74.2% YoY Gross margin
59.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Organon & Co. Q2 FY2023 Earnings Call
Revenue
$1.61B
▲ 1.5% YoY Diluted EPS
$0.95
▲ 3.3% YoY Gross margin
60.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Organon & Co. Q1 FY2023 Earnings Call
Revenue
$1.54B
▼ 1.9% YoY Diluted EPS
$0.69
▼ 49.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-16
Organon & Co. Q4 FY2022 Earnings Call
Revenue
$1.49B*
▼ 7.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Organon & Co. Q3 FY2022 Earnings Call
Revenue
$1.54B
▼ 3.9% YoY Diluted EPS
$0.89
▼ 29.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Organon & Co. Q2 FY2022 Earnings Call
Revenue
$1.58B
▼ 0.6% YoY Diluted EPS
$0.92
▼ 45.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Organon & Co. Q1 FY2022 Earnings Call
Revenue
$1.57B
▲ 4.1% YoY Diluted EPS
$1.36
▼ 13.9% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
Organon & Co. Q4 FY2021 Earnings Call
Revenue
$1.60B*
▼ 0.6% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-12
Organon & Co. Q3 FY2021 Earnings Call
Revenue
$1.60B
▼ 0.8% YoY Diluted EPS
$1.27
▼ 41.2% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Organon & Co. Q2 FY2021 Earnings Call
Revenue
$1.59B
▲ 4.5% YoY Diluted EPS
$1.68
▼ 21.5% YoY
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 earnings calls
Key facts
CIK
1821825
CUSIP
68622V106
13F (30d)
582 filings
558 filers
Visit website
Investor relations